Loading clinical trials...
Loading clinical trials...
A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
Conditions
Interventions
ALKS 8700
Dimethyl Fumarate
Locations
67
United States
Alkermes Investigational Site
Cullman, Alabama, United States
Alkermes Investigational Site
Phoenix, Arizona, United States
Alkermes Investigational Site
Tucson, Arizona, United States
Alkermes Investigational Site
Long Beach, California, United States
Alkermes Investigational Site
San Diego, California, United States
Alkermes Investigational Site
Basalt, Colorado, United States
Start Date
March 15, 2017
Primary Completion Date
June 27, 2019
Completion Date
June 27, 2019
Last Updated
July 14, 2020
NCT04047628
NCT04602390
NCT05978531
NCT04225312
NCT03536559
NCT05446285
Lead Sponsor
Biogen
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions